Board composition At the date of this report, there are ten directors on the Board, comprising nine independent non‑executive directors and one executive director. Throughout the year there was a maximum of ten directors on the Board. Since 1 July 2024 to the date of this report, the following changes to directorships occurred: • Ms Elaine Sorg joined the Board as a non‑executive director on 1 September 2024; • Dr Brian McNamee, Professor Andrew Cuthbertson and Ms Alison Watkins were re‑elected as non‑executive directors at the 2024 Annual General Meeting, held on 29 October 2024; • Ms Elaine Sorg and Ms Samantha Lewis were elected as non-executive directors at the 2024 Annual General Meeting, held on 29 October 2024; • Professor Duncan Maskell retired from the Board as a non‑executive director on 29 October 2024; • Dr Brian Daniels joined the Board as a non-executive director on 1 December 2024; and • On 10 June 2025, CSL announced that Mr Cameron Price will join the Board as a non-executive director on 1 October 2025. The Board is focused on maintaining an appropriate mix of skills and diversity in its membership. This includes a range of skills, experience and background in the pharmaceutical industry, international business, finance and accounting, and management. A detailed matrix of Board skills is available in CSL’s FY2025 Corporate Governance Statement available at CSL.com. Audit and Risk Management Innovation and Development Corporate Governance and Nomination Human Resources and Remuneration CEO & Managing Director Global Leadership Group Company Secretary Board Collaboration Superior Performance Innovation Integrity Patient Focus Our Values Key Stakeholders, including Shareholders Board Committees Code of Responsible Business Practice 41 CSL Limited Annual Report 2024/25 + READ MORE AT CSL.COM/WE-ARE-CSL/ CORPORATE-GOVERNANCE
RkJQdWJsaXNoZXIy MjE2NDg3